Evonik Develops Biodegradable Drug-Delivery Polymers for Next-Generation Pharmaceuticals

Evonik is developing a new generation of biodegradable drug-delivery polymers that could help pharmaceutical manufacturers address environmental concerns without compromising essential formulation performance. The company's next-generation EUDRAGIT platform aims to combine biodegradability with the solubility enhancement and delayed-release properties that formulators require for oral medicines.

Evonik

The development highlights a growing opportunity for the specialty chemicals industry. Pharmaceutical companies increasingly need materials that support product quality, reliable drug release and environmental responsibility, creating new considerations for procurement managers, excipient distributors and chemical suppliers.

For buyers, the key question is how biodegradable pharmaceutical polymers will perform in commercial formulations and what their development means for future sourcing strategies. Evonik's initiative offers an early indication of how sustainability requirements could influence the next generation of functional pharmaceutical materials.

1. Evonik's Biodegradable EUDRAGIT Platform Targets Pharmaceutical Sustainability

Evonik's initiative focuses on developing biodegradable polymers for oral drug delivery, building on the company's established EUDRAGIT technology. These functional materials help pharmaceutical manufacturers control how active ingredients behave after administration, including when and how a medicine releases its contents.

Traditional pharmaceutical polymers can provide dependable performance across different dosage forms. However, their environmental characteristics have become an additional consideration for manufacturers seeking to improve the sustainability profile of finished medicines.

Evonik aims to address this challenge by designing polymers that combine established pharmaceutical functionality with a biodegradable end-of-life profile. The company wants formulators to retain the practical advantages of existing materials while gaining another option for environmentally conscious product development.

This approach matters because pharmaceutical companies cannot select excipients based on sustainability alone. Any replacement material must also satisfy formulation requirements, manufacturing specifications and product quality expectations.

The new platform therefore represents a development in functional material design rather than simply a change in raw material composition. For chemical traders and procurement teams, it introduces a potential future category of specialty pharmaceutical polymers to monitor.

2. Why Biodegradable Drug-Delivery Polymers Matter

Pharmaceutical excipients play an important role in determining the performance of medicines. Although active pharmaceutical ingredients produce the intended therapeutic effect, excipients help manufacturers achieve the physical, chemical and release characteristics required for a particular dosage form.

Functional polymers can support several important formulation objectives:

• Controlled drug release: Polymer coatings help manufacturers design medicines that release active ingredients according to a specified profile.

• Solubility enhancement: Selected polymers help improve the formulation of poorly soluble drug substances, which can present challenges during product development.

• Protection and stability: Appropriate coating systems can help protect active ingredients from specific environmental conditions encountered during storage or gastrointestinal transit.

• Manufacturing consistency: Reliable polymer properties help formulators maintain reproducible processing and product quality across production batches.

Biodegradability adds another consideration to this established list of requirements. A polymer designed to break down under defined environmental conditions may help reduce long-term material persistence after use and disposal.

For pharmaceutical manufacturers, the objective is to integrate this environmental characteristic without sacrificing the functionality that makes a polymer useful. For procurement teams, that creates a need to evaluate performance and sustainability together rather than treating them as separate purchasing decisions.

3. Maintaining Solubility Enhancement and Delayed Release

One of the central challenges in pharmaceutical polymer development is balancing environmental characteristics with precise drug-delivery performance. Evonik's new platform targets two particularly important functions, solubility enhancement and delayed release.

Solubility enhancement matters when an active pharmaceutical ingredient does not dissolve readily in the conditions needed for effective formulation. Selected polymer systems can help manufacturers develop suitable dosage forms for these challenging compounds.

Delayed-release coatings serve a different purpose. They help control when a medicine releases its active ingredient, allowing formulators to design products that postpone release until the dosage form reaches an intended environment or meets a defined release condition.

These functions require carefully controlled material properties. Changes in polymer composition can influence solubility, film formation, processing behavior and release characteristics, so formulators must evaluate the complete system rather than relying on a single material specification.

Evonik's objective is to preserve the established performance associated with EUDRAGIT while introducing biodegradability as an additional design feature. If the new materials achieve that balance in practical formulations, pharmaceutical developers could gain greater flexibility when designing products with environmental considerations in mind.

For buyers, the distinction between a promising material concept and a qualified commercial ingredient remains important. A polymer must demonstrate consistent quality and formulation suitability before manufacturers can incorporate it into routine production.

4. OECD Biodegradability Criteria and Material Evaluation

Environmental performance needs clear testing criteria if pharmaceutical manufacturers want to compare materials and support sustainability decisions. Evonik's development program uses established biodegradability testing methods to assess the new polymer platform.

The company reports that the polymers meet biodegradability criteria under OECD 301 F and OECD 301 B, with results exceeding 60%. These standardized tests provide a framework for evaluating biodegradation under specified test conditions.

Evonik

For pharmaceutical procurement professionals, the use of recognized testing methods provides a more structured basis for reviewing environmental claims. Buyers can use the available technical documentation to understand the test conditions, results and applicability to their intended material selection.

However, biodegradability is only one part of a pharmaceutical excipient's technical profile. Buyers should also assess:

• Material specifications: Confirm identity, purity, physical properties and applicable pharmaceutical quality requirements.

• Formulation compatibility: Determine whether the polymer works with the active ingredient and other excipients.

• Processing requirements: Review compatibility with coating, extrusion, spray drying or other relevant manufacturing methods.

• Environmental evidence: Examine test results and determine whether the stated biodegradation conditions align with the intended sustainability assessment.

Implications for Pharmaceutical Manufacturers and Chemical Buyers

The development of biodegradable drug-delivery polymers could influence purchasing decisions across the pharmaceutical supply chain. Manufacturers may increasingly evaluate excipients not only on cost and technical performance but also on their contribution to environmental objectives.

For procurement managers, this creates several practical considerations.

First, technical qualification remains essential. A biodegradable polymer must meet the formulation's performance requirements and fit the manufacturer's established quality systems. Buyers should work closely with research and development teams before considering any material substitution.

Second, supply availability will influence purchasing plans. Evonik has indicated that non-commercial, laboratory-scale quantities are available for joint development projects with selected partners. This positions the current offering as a development opportunity rather than a standard commodity available for unrestricted commercial procurement.

Evonik

Third, cost comparisons must reflect total formulation requirements. Buyers should consider material pricing alongside processing performance, qualification expenses, testing needs and any changes required in manufacturing procedures.

Fourth, supplier technical support can affect project timelines. Access to formulation guidance, application data and consistent product documentation can help manufacturers assess new materials more efficiently.

Chemical distributors can also monitor this emerging segment. Pharmaceutical customers may eventually seek qualified sourcing channels for functional polymers with defined environmental characteristics, although demand will depend on technical validation, commercial availability and adoption by drug manufacturers.

6. Supply Chain Readiness, Qualification and Commercial Opportunities

Biodegradable pharmaceutical polymers belong to a specialized segment of the chemicals market. Unlike widely traded commodity chemicals, these materials require application-specific technical evaluation and close coordination between material developers and pharmaceutical customers.

That distinction affects how buyers should approach sourcing. Price and delivery schedules remain important, but material consistency, documentation and technical support can carry greater weight when a polymer forms part of a controlled-release medicine.

Procurement teams evaluating this category should consider the following priorities:

• Supplier qualification: Establish the manufacturer's quality requirements and confirm which documentation is available for the specific material.

• Sample evaluation: Request development quantities through appropriate supplier channels and coordinate testing with formulation specialists.

• Commercial planning: Clarify whether the material remains at laboratory scale or has progressed to broader commercial supply.

• Supply continuity: Discuss production capacity, lead times and future availability before incorporating the material into long-term purchasing plans.

• Regulatory alignment: Determine what evidence is needed to support excipient qualification and any relevant product registration activities.

These steps can help buyers distinguish an early-stage innovation from a material that is ready for routine purchasing. They also provide a framework for evaluating future biodegradable polymer offerings from other specialty chemical manufacturers.

For importers and exporters, the immediate opportunity lies in understanding customer requirements and identifying suppliers with suitable pharmaceutical material portfolios. Building technical familiarity early can help trading companies respond more effectively as demand develops.

7. What the Development Means for the Specialty Chemicals Market

Evonik's initiative illustrates how sustainability considerations are influencing the design of high-value specialty chemicals. Rather than focusing exclusively on conventional performance targets, material developers are exploring ways to combine functional properties with improved environmental behavior.

This trend may affect how pharmaceutical companies define acceptable excipient specifications. Environmental characteristics could become an additional selection criterion alongside purity, functionality, processability and supply reliability.

The market opportunity also extends beyond the polymer manufacturer. Pharmaceutical developers, contract manufacturers, excipient distributors and specialist testing providers may all play roles in assessing and adopting new materials.

However, commercial adoption will depend on practical results. Formulation performance, manufacturing compatibility, quality requirements and material availability will determine whether biodegradable alternatives can move from collaborative development into wider pharmaceutical use.

For chemical traders, this makes technical market intelligence particularly valuable. Monitoring development milestones and understanding customer qualification requirements can help identify potential opportunities without treating early-stage materials as established commercial products.

8. What Procurement Teams Should Do Next

Evonik's biodegradable EUDRAGIT platform presents pharmaceutical manufacturers with a potential route to combine established drug-delivery functions with improved biodegradability. Its significance lies in the effort to integrate environmental performance into the design of functional excipients while retaining the properties that formulators depend on.

Procurement teams should begin by identifying applications where polymer sustainability is becoming a material selection priority. They can then work with research and development, quality assurance and regulatory colleagues to define technical requirements and evaluate suitable development partners.

Buyers should also distinguish between laboratory-scale development materials and commercially available products. This distinction helps prevent premature sourcing commitments and supports realistic planning for qualification, supply continuity and future purchasing volumes.

For chemical distributors and B2B suppliers, the development reinforces the importance of specialized product knowledge. Understanding pharmaceutical polymer functions, technical documentation and customer qualification processes can create a stronger foundation for serving manufacturers as sustainable formulation technologies evolve.

The next stage will depend on development progress, customer testing and broader commercial readiness. Companies that follow these developments closely will be better positioned to assess where biodegradable functional polymers fit into their future sourcing strategies.